S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
(Ad)
2020 could be a monster year for cannabis stocks, especially with cannabis on many November ballots, and presidential candidates pushing for approval. In our latest special report, we detail five must-own cannabis stocks that could double, even triple your investment over the next year.

NASDAQ:NTGN - Neon Therapeutics Stock Price, Forecast & News

$1.69
-0.01 (-0.59 %)
(As of 01/20/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.63
Now: $1.69▼
$1.80
50-Day Range
$0.94
MA: $1.17▼
$1.70
52-Week Range
$0.88
Now: $1.69▼
$7.51
Volume957,729 shs
Average Volume477,325 shs
Market Capitalization$47.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTGN
Previous Symbol
CUSIPN/A
CIKN/A
Webhttp://www.neontherapeutics.com/
Phone617-337-4701

Debt

Debt-to-Equity Ratio0.15
Current Ratio4.59
Quick Ratio4.59

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.58 per share
Price / Book0.47

Profitability

EPS (Most Recent Fiscal Year)($5.54)
Net Income$-76,930,000.00
Net MarginsN/A
Return on Equity-116.98%
Return on Assets-95.27%

Miscellaneous

Employees102
Outstanding Shares28,340,000
Market Cap$47.89 million
Next Earnings Date3/9/2020 (Estimated)
OptionableNot Optionable

Receive NTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for NTGN and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:NTGN Rates by TradingView

(Ad)


A U.S. congressional committee passed important legislation that enables each state to set its own policies around cannabis… This bill also allows states to expunge federal marijuana convictions and arrests. This will likely lead to federal legalization sooner than expected. Get in early and you just might be the next 'Marijuana Millionaire'...

Neon Therapeutics (NASDAQ:NTGN) Frequently Asked Questions

What is Neon Therapeutics' stock symbol?

Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN."

How were Neon Therapeutics' earnings last quarter?

Neon Therapeutics Inc (NASDAQ:NTGN) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.68) EPS for the quarter, missing the Zacks' consensus estimate of ($0.64) by $0.04. View Neon Therapeutics' Earnings History.

When is Neon Therapeutics' next earnings date?

Neon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Neon Therapeutics.

What price target have analysts set for NTGN?

6 brokerages have issued 1-year price objectives for Neon Therapeutics' shares. Their forecasts range from $7.00 to $15.00. On average, they expect Neon Therapeutics' stock price to reach $12.40 in the next year. This suggests a possible upside of 633.7% from the stock's current price. View Analyst Price Targets for Neon Therapeutics.

What is the consensus analysts' recommendation for Neon Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neon Therapeutics.

What are Wall Street analysts saying about Neon Therapeutics stock?

Here are some recent quotes from research analysts about Neon Therapeutics stock:
  • 1. According to Zacks Investment Research, "Neon Therapeutics Inc. is a clinical-stage immuno-oncology company. It engaged in developing neoantigen-based therapeutics for the treatment of cancer by directing the immune system. The company's product pipeline consists of NEO-PV-01, NEO-PTC-01 and NEO-SV-01 which are in clinical stage. Neon Therapeutics Inc. is based in Cambridge, United States. " (1/4/2020)
  • 2. HC Wainwright analysts commented, "Our assessment is driven by a discounted cash flow (DCF)-based approach, which utilizes a 10% discount rate, 1.0% terminal growth rate, and 30% probability of approval for NEO-PV-01 in front-line melanoma, NSCLC, and bladder cancer. We assume a 29% effective tax rate." (9/16/2019)

Has Neon Therapeutics been receiving favorable news coverage?

News coverage about NTGN stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neon Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Neon Therapeutics.

Are investors shorting Neon Therapeutics?

Neon Therapeutics saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 573,900 shares, a decrease of 19.6% from the December 15th total of 713,900 shares. Based on an average daily volume of 204,700 shares, the days-to-cover ratio is currently 2.8 days. Currently, 4.0% of the shares of the stock are sold short. View Neon Therapeutics' Current Options Chain.

Who are some of Neon Therapeutics' key competitors?

What other stocks do shareholders of Neon Therapeutics own?

Who are Neon Therapeutics' key executives?

Neon Therapeutics' management team includes the folowing people:
  • Mr. Hugh O'Dowd, Pres, CEO & Director (Age 54)
  • Dr. Eric S. Lander, Founder & Director (Age 62)
  • Dr. Yasir B. Al-Wakeel, Chief Financial Officer (Age 37)
  • Dr. Richard Gaynor, Pres of R&D (Age 69)
  • Dr. Edward Fritsch Ph.D., Founder and Chief Technology Officer

When did Neon Therapeutics IPO?

(NTGN) raised $101 million in an IPO on Wednesday, June 27th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as the underwriters for the IPO and Oppenheimer was co-manager.

Who are Neon Therapeutics' major shareholders?

Neon Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FNY Investment Advisers LLC (0.88%). Company insiders that own Neon Therapeutics stock include Access Industries Holdings Llc and Richard Gaynor. View Institutional Ownership Trends for Neon Therapeutics.

Which major investors are buying Neon Therapeutics stock?

NTGN stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View Insider Buying and Selling for Neon Therapeutics.

How do I buy shares of Neon Therapeutics?

Shares of NTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neon Therapeutics' stock price today?

One share of NTGN stock can currently be purchased for approximately $1.69.

How big of a company is Neon Therapeutics?

Neon Therapeutics has a market capitalization of $47.89 million. The company earns $-76,930,000.00 in net income (profit) each year or ($5.54) on an earnings per share basis. Neon Therapeutics employs 102 workers across the globe.View Additional Information About Neon Therapeutics.

What is Neon Therapeutics' official website?

The official website for Neon Therapeutics is http://www.neontherapeutics.com/.

How can I contact Neon Therapeutics?

Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected]


MarketBeat Community Rating for Neon Therapeutics (NASDAQ NTGN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  153 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  295
MarketBeat's community ratings are surveys of what our community members think about Neon Therapeutics and other stocks. Vote "Outperform" if you believe NTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: What is a back-end load?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel